A randomized controlled trial of pegylated interferon-alpha with tenofovir disoproxil fumarate for hepatitis B e antigen-negative chronic hepatitis B: A 48-week follow-up study

Background: Recent studies have reported findings regarding the addition of pegylated interferon aligned -alpha (Peg- IFNα) to nucleos (t) analog ideas. This study was designed to compare the efficacy of Peg- IFNα therapy and tenofovir disoproxil fumarate (TDF) in combination with each treatment separately.


Methods: In this open-label, randomized clinical trial, treatment-naive hepatitis B e antigen (HBeAg) -negative patients were randomly assigned to three treatment groups: Group A: Peg- IFNα (180 mcg / week) with TDF (300 mg / day); Group B: TDF (300 mg / day); and Group C: Peg- IFNα (180 mcg / week). intervention runs 48 weeks and patients were followed every 12 weeks. Primary endpoint was the burden of HBV DNA <20 IU / mL.


Results: Group A, B and C, each consisting of 22, 23 and 22 patients, respectively. The number of patients with HBV DNA suppression in group A was significantly higher than in group B and C (P = 0.034). No significant differences were observed in the trend of normalization of serum ALT levels between the three groups (P = 0.082). At week 48, the combination therapy was significantly more effective in suppressing HBV DNA concentrations below detection levels of TDF monotherapy (OR = 2.1, 95% CI: 1.18 to 4.15; P = 0.034). In addition, the comparison between the monotherapy arm revealed that both interventions have the same effect on the overall outcome (OR = 1.24, 95% CI: 1.02 to 5.8; P = 0.062).


Conclusion: A Peg- IFNα and TDF combination therapy resulted in a good and safe virologic response in patients with HBeAg negative. Monotherapy with Peg-IFNα or TDF benefit was limited compared.

 A randomized controlled trial of pegylated interferon-alpha with tenofovir disoproxil fumarate for hepatitis B e antigen-negative chronic hepatitis B: A 48-week follow-up study
A randomized controlled trial of pegylated interferon-alpha with tenofovir disoproxil fumarate for hepatitis B e antigen-negative chronic hepatitis B: A 48-week follow-up study

Double-blind, randomized trial to compare the efficacy of escitalopram compared to citalopram for depression induced interferon in patients with hepatitis C

Objective: The objective of this study was to compare two antidepressant drug citalopram and escitalopram on the basis of success in depressed patients of hepatitis C patients who received interferon.


Methods: In a double-blind randomized trial, patients with hepatitis C visit the National institute liver and gastro intestinal diseases (NILGID), Dow University Hospital, screened for depression before starting treatment with interferon. Institutional review board approval was obtained and references no.is mail: IRB-682 / DUHS / approval / 2016/169. Patients with a history of depression were excluded from the study. The patients who started therapy with interferon assessed for depression at baseline and then at each visit. Those who develop depression were randomly assigned to receive either citalopram or escitalopram. treatment groups was assessed by a scale of depression every time they visit the clinic. Two antidepressants compared to their success in an interval of 4 weeks, 8weeks and then 12 weeks.

IFNA4 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC)

LV647513 1.0 ug DNA
EUR 616.8

IFNA1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)

LV683185 1.0 ug DNA
EUR 616.8

IFNA1 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC)

LV683189 1.0 ug DNA
EUR 616.8

IFNA11P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)

LV763643 1.0 ug DNA
EUR 1173.6

IFNA11P Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)

LV763647 1.0 ug DNA
EUR 1173.6

IFNA12P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)

LV763649 1.0 ug DNA
EUR 1173.6

IFNA12P Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)

LV763653 1.0 ug DNA
EUR 1173.6

IFNA22P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)

LV763655 1.0 ug DNA
EUR 1173.6

IFNA22P Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)

LV763659 1.0 ug DNA
EUR 1173.6

IFNA20P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)

LV729275 1.0 ug DNA Ask for price

IFNA20P Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)

LV729279 1.0 ug DNA Ask for price

IFNA4 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a)

LV647514 1.0 ug DNA
EUR 616.8

IFNA1 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a)

LV683190 1.0 ug DNA
EUR 616.8

IFNA4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)

LV706467 1.0 ug DNA
EUR 540

IFNA4 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)

LV706471 1.0 ug DNA
EUR 540

IFNA1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)

LV706491 1.0 ug DNA
EUR 540

IFNA1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)

LV706495 1.0 ug DNA
EUR 540

IFNA11P Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a)

LV763648 1.0 ug DNA
EUR 1173.6

IFNA12P Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a)

LV763654 1.0 ug DNA
EUR 1173.6

IFNA22P Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a)

LV763660 1.0 ug DNA
EUR 1173.6

IFNA20P Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a)

LV729280 1.0 ug DNA Ask for price

IFNA4 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a)

LV706472 1.0 ug DNA
EUR 540

IFNA1 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a)

LV706496 1.0 ug DNA
EUR 540

IFNA13 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)

LV791922 1.0 ug DNA
EUR 448.8

IFNA16 Protein Vector (Human) (pPM-C-HA)

PV085431 500 ng Ask for price

IFNA16 Protein Vector (Human) (pPB-C-His)

PV085429 500 ng Ask for price

IFNA16 Protein Vector (Human) (pPB-N-His)

PV085430 500 ng Ask for price

IFNA16 Protein Vector (Human) (pPM-C-His)

PV085432 500 ng Ask for price

IFNA4 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA)

LV647510 1.0 ug DNA
EUR 616.8

IFNA1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA)

LV683186 1.0 ug DNA
EUR 616.8

IFNA11P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA)

LV763644 1.0 ug DNA
EUR 1173.6

IFNA12P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA)

LV763650 1.0 ug DNA
EUR 1173.6

IFNA22P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA)

LV763656 1.0 ug DNA
EUR 1173.6

IFNA20P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA)

LV729276 1.0 ug DNA Ask for price

IFNA11P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)

LV763645 1.0 ug DNA
EUR 1243.2

IFNA11P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)

LV763646 1.0 ug DNA
EUR 1243.2

IFNA12P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)

LV763651 1.0 ug DNA
EUR 1243.2

IFNA12P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)

LV763652 1.0 ug DNA
EUR 1243.2

IFNA22P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)

LV763657 1.0 ug DNA
EUR 1243.2

IFNA22P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)

LV763658 1.0 ug DNA
EUR 1243.2

IFNA20P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)

LV729277 1.0 ug DNA Ask for price

IFNA20P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)

LV729278 1.0 ug DNA Ask for price

IFNA4 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)

LV647511 1.0 ug DNA
EUR 686.4

IFNA4 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)

LV647512 1.0 ug DNA
EUR 686.4

IFNA1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)

LV683187 1.0 ug DNA
EUR 686.4

IFNA1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)

LV683188 1.0 ug DNA
EUR 686.4

IFNA4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA)

LV706468 1.0 ug DNA
EUR 540

IFNA1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA)

LV706492 1.0 ug DNA
EUR 540

IFNA16 siRNA

20-abx920220
  • EUR 661.20
  • EUR 878.40
  • 15 nmol
  • 30 nmol

IFNA4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)

LV706469 1.0 ug DNA
EUR 609.6

IFNA4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)

LV706470 1.0 ug DNA
EUR 609.6

IFNA1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)

LV706493 1.0 ug DNA
EUR 609.6

IFNA1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)

LV706494 1.0 ug DNA
EUR 609.6

IFNA16 Antibody

37641-100ul 100ul
EUR 302.4

IFNA16 Antibody

1-CSB-PA689914
  • EUR 380.40
  • EUR 292.80
  • 100ul
  • 50ul
Description: A polyclonal antibody against IFNA16. Recognizes IFNA16 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB;ELISA:1:2000-1:5000, WB:1:500-1:2000

IFNA16 Antibody

1-CSB-PA011036LA01HU
  • EUR 380.40
  • EUR 402.00
  • 100ul
  • 50ul
Description: A polyclonal antibody against IFNA16. Recognizes IFNA16 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200

IFNA16 sgRNA CRISPR Lentivector set (Human)

K1020001 3 x 1.0 ug
EUR 406.8

IFNA16 Conjugated Antibody

C37641 100ul
EUR 476.4

IFNA16 sgRNA CRISPR Lentivector (Human) (Target 1)

K1020002 1.0 ug DNA
EUR 184.8

IFNA16 sgRNA CRISPR Lentivector (Human) (Target 2)

K1020003 1.0 ug DNA
EUR 184.8

IFNA16 sgRNA CRISPR Lentivector (Human) (Target 3)

K1020004 1.0 ug DNA
EUR 184.8

IFNAR1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)

LV640375 1.0 ug DNA
EUR 818.4

IFNAR1 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC)

LV640379 1.0 ug DNA
EUR 818.4

Human IFNA16 shRNA Plasmid

20-abx952338
  • EUR 961.20
  • EUR 1345.20
  • 150 µg
  • 300 µg

IFNAR1 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a)

LV640380 1.0 ug DNA
EUR 818.4

IFNA16 Antibody, HRP conjugated

1-CSB-PA011036LB01HU
  • EUR 380.40
  • EUR 402.00
  • 100ul
  • 50ul
Description: A polyclonal antibody against IFNA16. Recognizes IFNA16 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA

IFNA16 Antibody, FITC conjugated

1-CSB-PA011036LC01HU
  • EUR 380.40
  • EUR 402.00
  • 100ul
  • 50ul
Description: A polyclonal antibody against IFNA16. Recognizes IFNA16 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA

IFNA16 Antibody, Biotin conjugated

1-CSB-PA011036LD01HU
  • EUR 380.40
  • EUR 402.00
  • 100ul
  • 50ul
Description: A polyclonal antibody against IFNA16. Recognizes IFNA16 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA

Interferon Alpha 16 (IFNA16) Antibody

20-abx211357
  • EUR 493.20
  • EUR 360.00
  • 100 ul
  • 50 ul

Recombinant Interferon Alpha 16 (IFNa16)

4-RPG968Mu01
  • EUR 636.10
  • EUR 294.00
  • EUR 2055.36
  • EUR 765.12
  • EUR 1410.24
  • EUR 501.60
  • EUR 4958.40
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
Description: Recombinant Mouse Interferon Alpha 16 expressed in: E.coli

IFNAR1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA)

LV640376 1.0 ug DNA
EUR 818.4

IFNA16 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)

K1020005 3 x 1.0 ug
EUR 451.2

IFNAR1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)

LV640377 1.0 ug DNA
EUR 888

IFNAR1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)

LV640378 1.0 ug DNA
EUR 888

IFNA16 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1)

K1020006 1.0 ug DNA
EUR 200.4

IFNA16 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2)

K1020007 1.0 ug DNA
EUR 200.4

IFNA16 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3)

K1020008 1.0 ug DNA
EUR 200.4

IFNA16 3'UTR GFP Stable Cell Line

TU060478 1.0 ml
EUR 1672.8

IFNA16 3'UTR Luciferase Stable Cell Line

TU010478 1.0 ml
EUR 1672.8

Human Interferon alpha- 16, IFNA16 ELISA KIT

ELI-48218h 96 Tests
EUR 988.8

Human Interferon Alpha 16(IFNa16)ELISA Kit

QY-E03458 96T
EUR 433.2

Human Interferon Alpha 16 (IFNa16) Protein (Active)

20-abx655681
  • EUR 1345.20
  • EUR 493.20
  • EUR 4468.80
  • EUR 1629.60
  • EUR 910.80
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

h IFNAR2 inducible lentiviral particles

LVP774 1x107 IFU/ml x 200ul
EUR 541.2
Description: Pre-made over-expression lentivirus for expressing human target: IFNAR2 (interferon (alpha, beta and omega) receptor 2), [alternative names: IFN-alpha-REC; IFN-R; IFNABR; IFNARB]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_207585.2. It also contains a RFP-Blasticidin dual selection marker.

IFNA13 ORF Vector (Human) (pORF)

ORF005213 1.0 ug DNA
EUR 114

IFNA21 ORF Vector (Human) (pORF)

ORF005214 1.0 ug DNA
EUR 114

IFNA10 ORF Vector (Human) (pORF)

ORF013324 1.0 ug DNA
EUR 424.8

IFNA14 ORF Vector (Human) (pORF)

ORF021357 1.0 ug DNA
EUR 486

IFNA17 ORF Vector (Human) (pORF)

ORF021359 1.0 ug DNA
EUR 486

Ifna11 ORF Vector (Mouse) (pORF)

ORF047683 1.0 ug DNA
EUR 607.2

Ifna12 ORF Vector (Mouse) (pORF)

ORF047684 1.0 ug DNA
EUR 607.2

Ifna13 ORF Vector (Mouse) (pORF)

ORF047685 1.0 ug DNA
EUR 607.2

Ifna14 ORF Vector (Mouse) (pORF)

ORF047686 1.0 ug DNA
EUR 607.2

IFNA11P ORF Vector (Human) (pORF)

ORF021355 1.0 ug DNA Ask for price

IFNA12P ORF Vector (Human) (pORF)

ORF021356 1.0 ug DNA Ask for price

IFNA20P ORF Vector (Human) (pORF)

ORF021361 1.0 ug DNA Ask for price

IFNA22P ORF Vector (Human) (pORF)

ORF021362 1.0 ug DNA Ask for price

Ifna1 ORF Vector (Rat) (pORF)

ORF068513 1.0 ug DNA
EUR 607.2

Ifna4 ORF Vector (Rat) (pORF)

ORF068514 1.0 ug DNA
EUR 607.2

IFNA13 Protein Vector (Human) (pPM-C-HA)

PV020851 500 ng
EUR 394.8

IFNA21 Protein Vector (Human) (pPM-C-HA)

PV020855 500 ng
EUR 394.8

IFNA10 Protein Vector (Human) (pPM-C-HA)

PV053295 500 ng
EUR 577.2

IFNA14 Protein Vector (Human) (pPM-C-HA)

PV085427 500 ng
EUR 662.4

IFNA17 Protein Vector (Human) (pPM-C-HA)

PV085435 500 ng
EUR 662.4

Ifna11 Protein Vector (Mouse) (pPM-C-HA)

PV190732 500 ng
EUR 723.6

Ifna12 Protein Vector (Mouse) (pPM-C-HA)

PV190736 500 ng
EUR 723.6

IFNA13 Protein Vector (Mouse) (pPM-C-HA)

PV190740 500 ng
EUR 723.6

IFNA14 Protein Vector (Mouse) (pPM-C-HA)

PV190744 500 ng
EUR 723.6

IFNA13 Protein Vector (Human) (pPB-C-His)

PV020849 500 ng
EUR 394.8

IFNA13 Protein Vector (Human) (pPB-N-His)

PV020850 500 ng
EUR 394.8

IFNA13 Protein Vector (Human) (pPM-C-His)

PV020852 500 ng
EUR 394.8

IFNA21 Protein Vector (Human) (pPB-C-His)

PV020853 500 ng
EUR 394.8

IFNA21 Protein Vector (Human) (pPB-N-His)

PV020854 500 ng
EUR 394.8

IFNA21 Protein Vector (Human) (pPM-C-His)

PV020856 500 ng
EUR 394.8

IFNA10 Protein Vector (Human) (pPB-C-His)

PV053293 500 ng
EUR 577.2

IFNA10 Protein Vector (Human) (pPB-N-His)

PV053294 500 ng
EUR 577.2

IFNA10 Protein Vector (Human) (pPM-C-His)

PV053296 500 ng
EUR 577.2

IFNA14 Protein Vector (Human) (pPB-C-His)

PV085425 500 ng
EUR 662.4

IFNA14 Protein Vector (Human) (pPB-N-His)

PV085426 500 ng
EUR 662.4

IFNA14 Protein Vector (Human) (pPM-C-His)

PV085428 500 ng
EUR 662.4

IFNA17 Protein Vector (Human) (pPB-C-His)

PV085433 500 ng
EUR 662.4

IFNA17 Protein Vector (Human) (pPB-N-His)

PV085434 500 ng
EUR 662.4

IFNA17 Protein Vector (Human) (pPM-C-His)

PV085436 500 ng
EUR 662.4

IFNA20P Protein Vector (Human) (pPM-C-HA)

PV085443 500 ng Ask for price

Ifna11 Protein Vector (Mouse) (pPB-C-His)

PV190730 500 ng
EUR 723.6

Ifna11 Protein Vector (Mouse) (pPB-N-His)

PV190731 500 ng
EUR 723.6

Ifna11 Protein Vector (Mouse) (pPM-C-His)

PV190733 500 ng
EUR 723.6

Ifna12 Protein Vector (Mouse) (pPB-C-His)

PV190734 500 ng
EUR 723.6

Ifna12 Protein Vector (Mouse) (pPB-N-His)

PV190735 500 ng
EUR 723.6

Ifna12 Protein Vector (Mouse) (pPM-C-His)

PV190737 500 ng
EUR 723.6

IFNA13 Protein Vector (Mouse) (pPB-C-His)

PV190738 500 ng
EUR 723.6

IFNA13 Protein Vector (Mouse) (pPB-N-His)

PV190739 500 ng
EUR 723.6

IFNA13 Protein Vector (Mouse) (pPM-C-His)

PV190741 500 ng
EUR 723.6

IFNA14 Protein Vector (Mouse) (pPB-C-His)

PV190742 500 ng
EUR 723.6

IFNA14 Protein Vector (Mouse) (pPB-N-His)

PV190743 500 ng
EUR 723.6

IFNA14 Protein Vector (Mouse) (pPM-C-His)

PV190745 500 ng
EUR 723.6

IFNA1 ORF Vector (Human) (pORF)

ORF013323 1.0 ug DNA
EUR 114

IFNA4 ORF Vector (Human) (pORF)

ORF013325 1.0 ug DNA
EUR 424.8

IFNA4 ORF Vector (Human) (pORF)

ORF013326 1.0 ug DNA
EUR 424.8

IFNA6 ORF Vector (Human) (pORF)

ORF013327 1.0 ug DNA
EUR 424.8

IFNA2 ORF Vector (Human) (pORF)

ORF021360 1.0 ug DNA
EUR 486

IFNA5 ORF Vector (Human) (pORF)

ORF021363 1.0 ug DNA
EUR 486

IFNA7 ORF Vector (Human) (pORF)

ORF021364 1.0 ug DNA
EUR 486

IFNA8 ORF Vector (Human) (pORF)

ORF021365 1.0 ug DNA
EUR 486

Ifna1 ORF Vector (Mouse) (pORF)

ORF047682 1.0 ug DNA
EUR 607.2

Ifna2 ORF Vector (Mouse) (pORF)

ORF047687 1.0 ug DNA
EUR 607.2

Ifna4 ORF Vector (Mouse) (pORF)

ORF047688 1.0 ug DNA
EUR 607.2

Ifna5 ORF Vector (Mouse) (pORF)

ORF047689 1.0 ug DNA
EUR 607.2

Ifna6 ORF Vector (Mouse) (pORF)

ORF047690 1.0 ug DNA
EUR 607.2

Ifna7 ORF Vector (Mouse) (pORF)

ORF047691 1.0 ug DNA
EUR 607.2

Ifna9 ORF Vector (Mouse) (pORF)

ORF047692 1.0 ug DNA
EUR 607.2

IFNA20P Protein Vector (Human) (pPB-C-His)

PV085441 500 ng Ask for price

IFNA20P Protein Vector (Human) (pPB-N-His)

PV085442 500 ng Ask for price

IFNA20P Protein Vector (Human) (pPM-C-His)

PV085444 500 ng Ask for price

IFNA1 Protein Vector (Rat) (pPM-C-HA)

PV274052 500 ng
EUR 723.6

IFNA4 Protein Vector (Rat) (pPM-C-HA)

PV274056 500 ng
EUR 723.6

IFNA1 Protein Vector (Rat) (pPB-C-His)

PV274050 500 ng
EUR 723.6

IFNA1 Protein Vector (Rat) (pPB-N-His)

PV274051 500 ng
EUR 723.6

IFNA1 Protein Vector (Rat) (pPM-C-His)

PV274053 500 ng
EUR 723.6

IFNA4 Protein Vector (Rat) (pPB-C-His)

PV274054 500 ng
EUR 723.6

IFNA4 Protein Vector (Rat) (pPB-N-His)

PV274055 500 ng
EUR 723.6

IFNA4 Protein Vector (Rat) (pPM-C-His)

PV274057 500 ng
EUR 723.6

IFNA1 Protein Vector (Human) (pPM-C-HA)

PV053291 500 ng
EUR 577.2

IFNA4 Protein Vector (Human) (pPM-C-HA)

PV053299 500 ng
EUR 577.2

IFNA4 Protein Vector (Human) (pPM-C-HA)

PV053303 500 ng
EUR 577.2

IFNA6 Protein Vector (Human) (pPM-C-HA)

PV053307 500 ng
EUR 577.2

IFNA2 Protein Vector (Human) (pPM-C-HA)

PV085439 500 ng
EUR 662.4

IFNA5 Protein Vector (Human) (pPM-C-HA)

PV085451 500 ng
EUR 662.4

IFNA7 Protein Vector (Human) (pPM-C-HA)

PV085455 500 ng
EUR 662.4

IFNA8 Protein Vector (Human) (pPM-C-HA)

PV085459 500 ng
EUR 662.4

IFNA1 Protein Vector (Mouse) (pPM-C-HA)

PV190728 500 ng
EUR 723.6

IFNA2 Protein Vector (Mouse) (pPM-C-HA)

PV190748 500 ng
EUR 723.6

IFNA4 Protein Vector (Mouse) (pPM-C-HA)

PV190752 500 ng
EUR 723.6

IFNA5 Protein Vector (Mouse) (pPM-C-HA)

PV190756 500 ng
EUR 723.6

IFNA6 Protein Vector (Mouse) (pPM-C-HA)

PV190760 500 ng
EUR 723.6

IFNA7 Protein Vector (Mouse) (pPM-C-HA)

PV190764 500 ng
EUR 723.6

Ifna9 Protein Vector (Mouse) (pPM-C-HA)

PV190768 500 ng
EUR 723.6

IFNA1 Protein Vector (Human) (pPB-C-His)

PV053289 500 ng
EUR 577.2

IFNA1 Protein Vector (Human) (pPB-N-His)

PV053290 500 ng
EUR 577.2

IFNA1 Protein Vector (Human) (pPM-C-His)

PV053292 500 ng
EUR 577.2

IFNA4 Protein Vector (Human) (pPB-C-His)

PV053297 500 ng
EUR 577.2

IFNA4 Protein Vector (Human) (pPB-N-His)

PV053298 500 ng
EUR 577.2

IFNA4 Protein Vector (Human) (pPM-C-His)

PV053300 500 ng
EUR 577.2

IFNA4 Protein Vector (Human) (pPB-C-His)

PV053301 500 ng
EUR 577.2

IFNA4 Protein Vector (Human) (pPB-N-His)

PV053302 500 ng
EUR 577.2

IFNA4 Protein Vector (Human) (pPM-C-His)

PV053304 500 ng
EUR 577.2

IFNA6 Protein Vector (Human) (pPB-C-His)

PV053305 500 ng
EUR 577.2

IFNA6 Protein Vector (Human) (pPB-N-His)

PV053306 500 ng
EUR 577.2

IFNA6 Protein Vector (Human) (pPM-C-His)

PV053308 500 ng
EUR 577.2

IFNA2 Protein Vector (Human) (pPB-C-His)

PV085437 500 ng
EUR 662.4

IFNA2 Protein Vector (Human) (pPB-N-His)

PV085438 500 ng
EUR 662.4


Results: In the present study 80 patients were randomized to receive either citalopram or escitalopram. The research result was better in patients treated with escitalopram. Significant changes in depression scores from the beginning to the end of the study was greater in the escitalopram group is 10.41 compared with citalopram group is 14.17. Differences in depression scores were also calculated as 4.28 and.3.76 (p <0.001) for both drugs at week 8 and week 12 respectively, which were statistically significant. Difference in depression scores were also calculated for the sex of 0.576 (p = 0.497) and age of 0.950 (p = 0.265), were found to be significant, statistically.


Conclusion: The results show the superiority of escitalopram over citalopram, the drug is twice as potent as racemic mixtures. In addition the drug is well tolerated and showed a better effect. Escitalopram proven to be a safer alternative to citalopram.